Litaty Céphanoée Mbatchi1,2,3, Jacques Robert4, Marc Ychou2,5, Jean-Christophe Boyer1, Maguy Del Rio2, Matthieu Gassiot1,2, Fabienne Thomas6, Nicole Tubiana7, Alexandre Evrard8,9,10. 1. Laboratoire de biochimie, Centre Hospitalier Universitaire de Nîmes, Hôpital Carémeau, Place du Professeur Robert Debré, 30029, Nîmes Cedex 9, France. 2. IRCM, Institut de Recherche en Cancérologie de Montpellier, INSERM U1194, Montpellier, France. 3. Laboratoire de Pharmacocinétique, Faculté de Pharmacie, Université de Montpellier, Montpellier, France. 4. INSERM U916, Institut Bergonié, Université de Bordeaux, Bordeaux, France. 5. Institut Régional du Cancer de Montpellier (ICM)-Val d'Aurelle, Montpellier, France. 6. EA4553 Institut Claudius-Regaud, and Université Paul-Sabatier, Toulouse, France. 7. Centre Hospitalier Universitaire de Limoges, Limoges Cedex, France. 8. Laboratoire de biochimie, Centre Hospitalier Universitaire de Nîmes, Hôpital Carémeau, Place du Professeur Robert Debré, 30029, Nîmes Cedex 9, France. alexandre.evrard@umontpellier.fr. 9. IRCM, Institut de Recherche en Cancérologie de Montpellier, INSERM U1194, Montpellier, France. alexandre.evrard@umontpellier.fr. 10. Laboratoire de Pharmacocinétique, Faculté de Pharmacie, Université de Montpellier, Montpellier, France. alexandre.evrard@umontpellier.fr.
Abstract
BACKGROUND AND OBJECTIVES: Nuclear receptors PXR (pregnane X receptor, NR1I2) and CAR (constitutive androstane receptor, NR1I3) are key regulators of irinotecan metabolism, and ligand-dependent modulation of their activity leads to significant drug-drug interactions. Because genetic polymorphisms can also affect the activity of these xenobiotic-sensing receptors, we hypothesized that they could contribute to the interpatient variability of irinotecan pharmacokinetics and to the toxicity of irinotecan-based regimens. PATIENTS AND METHODS: In a cohort of 109 metastatic colorectal cancer patients treated with irinotecan (180 mg/m(2)) in combination with other drugs, associations were assessed between 21 selected single nucleotide polymorphisms of NR1I2 or NR1I3 and pharmacokinetic parameters or toxicity of irinotecan and its metabolites. RESULTS: After adjustment of the tests by the UGT1A1*28 genotype and correction for multiple testing, the A allele of NR1I2-rs10934498 was associated with a decreased exposition and an increased degradation of SN-38, the active metabolite (p = 0.009 and p = 0.017, respectively). The risk of hematological toxicity was associated with NR1I2-rs10934498 and NR1I2-rs2472677 (p = 0.009 and p = 0.003, respectively). CONCLUSION: Our results reveal for the first time the involvement of NR1I2 in the pharmacogenetics of irinotecan and suggest that it may help to predict the toxicity of low-dose irinotecan.
BACKGROUND AND OBJECTIVES: Nuclear receptors PXR (pregnane X receptor, NR1I2) and CAR (constitutive androstane receptor, NR1I3) are key regulators of irinotecan metabolism, and ligand-dependent modulation of their activity leads to significant drug-drug interactions. Because genetic polymorphisms can also affect the activity of these xenobiotic-sensing receptors, we hypothesized that they could contribute to the interpatient variability of irinotecan pharmacokinetics and to the toxicity of irinotecan-based regimens. PATIENTS AND METHODS: In a cohort of 109 metastatic colorectal cancerpatients treated with irinotecan (180 mg/m(2)) in combination with other drugs, associations were assessed between 21 selected single nucleotide polymorphisms of NR1I2 or NR1I3 and pharmacokinetic parameters or toxicity of irinotecan and its metabolites. RESULTS: After adjustment of the tests by the UGT1A1*28 genotype and correction for multiple testing, the A allele of NR1I2-rs10934498 was associated with a decreased exposition and an increased degradation of SN-38, the active metabolite (p = 0.009 and p = 0.017, respectively). The risk of hematological toxicity was associated with NR1I2-rs10934498 and NR1I2-rs2472677 (p = 0.009 and p = 0.003, respectively). CONCLUSION: Our results reveal for the first time the involvement of NR1I2 in the pharmacogenetics of irinotecan and suggest that it may help to predict the toxicity of low-dose irinotecan.
Authors: Federico Innocenti; Richard L Schilsky; Jacqueline Ramírez; Linda Janisch; Samir Undevia; Larry K House; Soma Das; Kehua Wu; Michelle Turcich; Robert Marsh; Theodore Karrison; Michael L Maitland; Ravi Salgia; Mark J Ratain Journal: J Clin Oncol Date: 2014-06-23 Impact factor: 44.544
Authors: S Bonora; S Rusconi; A Calcagno; M Bracchi; O Viganò; J Cusato; M Lanzafame; A Trentalange; L Marinaro; M Siccardi; A D'Avolio; M Galli; G Di Perri Journal: J Antimicrob Chemother Date: 2015-07-14 Impact factor: 5.790
Authors: L B Moore; D J Parks; S A Jones; R K Bledsoe; T G Consler; J B Stimmel; B Goodwin; C Liddle; S G Blanchard; T M Willson; J L Collins; S A Kliewer Journal: J Biol Chem Date: 2000-05-19 Impact factor: 5.157
Authors: R H Mathijssen; R J van Alphen; J Verweij; W J Loos; K Nooter; G Stoter; A Sparreboom Journal: Clin Cancer Res Date: 2001-08 Impact factor: 12.531
Authors: Silvia Sookoian; Gustavo O Castaño; Adriana L Burgueño; Tomas Fernández Gianotti; María Soledad Rosselli; Carlos Jose Pirola Journal: Pharmacogenet Genomics Date: 2010-01 Impact factor: 2.089
Authors: M Ychou; F Viret; A Kramar; F Desseigne; E Mitry; R Guimbaud; J R Delpero; M Rivoire; F Quénet; G Portier; B Nordlinger Journal: Cancer Chemother Pharmacol Date: 2007-09-28 Impact factor: 3.333